Profusa Files S-1 for $100M Equity Facility, Bitcoin Purchase Plan

TL;DR

**Profusa's S-1 signals a high-risk, high-reward play, leveraging a $100M equity line for R&D and a speculative Bitcoin treasury strategy.**

AI Summary

Profusa, Inc. (formerly NorthView Acquisition Corporation) filed an S-1 on October 9, 2025, primarily for the resale of up to 42,594,048 shares of common stock. This includes 42,211,548 shares that may be sold to Ascent Partners Fund LLC under a July 28, 2025, Purchase Agreement, and 382,500 shares issued for transaction costs from the July 11, 2025, Business Combination. The company can sell up to $100,000,000 worth of common stock to Ascent over 36 months, with each sale priced at 97% of the lowest VWAP during a valuation period, subject to a $5,000,000 per closing limit or 100% of the average daily traded value for the preceding five days. Proceeds from these sales, if the cash balance exceeds $5,000,000, will be used to purchase Bitcoin for debt repayment; otherwise, they will first replenish the cash balance to $5,000,000. Profusa is developing biointegrated sensors, including the Lumee Oxygen Platform, already offered in the EU, and the Lumee Glucose Platform, a continuous glucose monitor designed for long-term use with a single injection.

Why It Matters

This S-1 filing reveals Profusa's strategy to secure up to $100,000,000 in funding through a committed equity facility with Ascent Partners Fund LLC, a significant move for a 'smaller reporting company' in the medical device sector. The unusual plan to use proceeds for Bitcoin purchases, contingent on cash balances, introduces a novel and potentially volatile element for investors. This financing mechanism could provide capital for their biointegrated sensor development, such as the Lumee Glucose Platform, but also exposes the company to cryptocurrency market fluctuations. Competitors in the continuous glucose monitoring space, like Dexcom and Abbott, will be watching how Profusa leverages this capital to advance its single-injection, long-term CGM technology.

Risk Assessment

Risk Level: high — The company explicitly states, 'Investing in our securities involves a high degree of risk.' The committed equity facility allows Profusa to sell shares at 97% of the lowest VWAP, which could lead to significant dilution for existing shareholders. Furthermore, the stated use of proceeds for Bitcoin purchases, if the cash balance exceeds $5,000,000, introduces substantial cryptocurrency market volatility risk to the company's financial health.

Analyst Insight

Investors should exercise extreme caution due to potential dilution from the committed equity facility and the speculative nature of using proceeds for Bitcoin. Monitor the company's cash balance and actual sales to Ascent, as well as the market price of Bitcoin, before considering any investment in PFSA.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

N/A

cash Position

$0

revenue Growth

N/A

Key Numbers

• 42,594,048 — Shares of Common Stock (Total shares registered for resale by Selling Stockholders)
• $100,000,000 — Maximum Aggregate Purchase Price (Total value of common stock Profusa may sell to Ascent)
• 97% — Purchase Price Percentage (Percentage of lowest VWAP for shares sold to Ascent)
• $0.33 — Last Sale Price (Profusa's common stock price on Nasdaq Global Market as of October 7, 2025)
• July 11, 2025 — Business Combination Date (Date Profusa completed its merger with NorthView Acquisition Corporation)
• July 28, 2025 — Purchase Agreement Date (Date Profusa entered into the Purchase Agreement with Ascent)
• 36 months — Term of Purchase Agreement (Period over which Profusa can sell shares to Ascent)
• 9.99% — Beneficial Ownership Limitation (Maximum percentage of outstanding shares Ascent can beneficially own)
• $5,000,000 — Cash Balance Threshold (Amount of cash balance required before proceeds are used for Bitcoin)

Key Players & Entities

• Profusa, Inc. (company) — Registrant and developer of biointegrated sensors
• Ascent Partners Fund LLC (company) — Selling Stockholder and counterparty to the Purchase Agreement
• Ben C. Hwang (person) — Chief Executive Officer of Profusa, Inc.
• NorthView Acquisition Corporation (company) — Former name of Profusa, Inc. before Business Combination
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Nasdaq Global Market (company) — Listing exchange for Profusa's common stock
• ArentFox Schiff LLP (company) — Legal counsel for Profusa, Inc.
• Bitcoin (dollar_amount) — Asset to be purchased with proceeds from equity sales

FAQ

Risk Factors

• Reliance on Committed Equity Facility [high — financial]: Profusa has entered into a committed equity facility with Ascent Partners Fund LLC, allowing it to sell up to $100,000,000 of common stock over 36 months. The pricing is set at 97% of the lowest VWAP during a valuation period, which could lead to significant dilution for existing shareholders and potentially depress the stock price.
• Product Development and Commercialization Risk [high — operational]: The company is developing novel biointegrated sensors, including the Lumee Glucose Platform, which is still in development. Commercial success depends on achieving regulatory approvals, market adoption, and scaling manufacturing, all of which carry inherent risks and uncertainties.
• Regulatory Hurdles for Medical Devices [high — regulatory]: Profusa's products, particularly the Lumee Glucose Platform, are medical devices requiring stringent regulatory approvals (e.g., FDA in the US). Delays or failures in obtaining these approvals can significantly impact the timeline to market and commercial viability.
• Use of Proceeds and Bitcoin Volatility [high — financial]: Proceeds from the equity facility, if cash exceeds $5,000,000, will be used to purchase Bitcoin for debt repayment. This introduces significant volatility and risk associated with Bitcoin's price fluctuations, potentially impacting the company's ability to meet its debt obligations.
• Competition in the Sensor Market [medium — market]: The markets for biosensors, including continuous glucose monitoring, are highly competitive with established players and emerging technologies. Profusa faces the challenge of differentiating its products and capturing market share.
• Dependence on Key Personnel [medium — operational]: The success of Profusa's technology development and commercialization efforts likely depends on the continued service of its key scientific and management personnel. The loss of such individuals could adversely affect the company's operations and prospects.
• Limited Operating History and Profitability [medium — financial]: As a company focused on developing new technologies, Profusa may have a limited operating history and may not yet be profitable. This increases the financial risk for investors, as future profitability is uncertain.
• Intellectual Property Risks [low — legal]: Protecting its intellectual property is crucial for Profusa. The company may face challenges in defending its patents or avoiding infringement claims from competitors, which could lead to costly litigation.

Industry Context

Profusa operates in the rapidly evolving medical device and diagnostics sector, specifically focusing on biointegrated sensors. Key areas include continuous monitoring for chronic conditions like diabetes. The market is characterized by significant R&D investment, stringent regulatory pathways (FDA, EMA), and intense competition from established players and innovative startups. Trends favor less invasive, longer-lasting, and more accurate monitoring solutions.

Regulatory Implications

As a developer of medical devices, Profusa faces significant regulatory scrutiny. Obtaining approvals from bodies like the FDA for its Lumee Glucose Platform is critical and can be a lengthy, costly process. Compliance with manufacturing standards (e.g., GMP) and data privacy regulations (e.g., HIPAA) are also essential for market access and operation.

What Investors Should Do

1. Monitor Bitcoin price volatility: Given the plan to use proceeds for Bitcoin purchases for debt repayment, investors should track Bitcoin's price movements as they directly impact Profusa's financial stability and debt management.
2. Evaluate dilution risk: The committed equity facility with Ascent allows for significant share sales at potentially discounted prices (97% of VWAP). Investors should assess the potential for substantial dilution of their ownership stake.
3. Track product development milestones: Key catalysts for Profusa's valuation will be progress in R&D, successful clinical trials, and regulatory approvals for its Lumee Glucose Platform. Monitor company announcements regarding these milestones.
4. Assess competitive landscape: Understand how Profusa's technology differentiates itself from existing and emerging competitors in the CGM and biosensor markets.
5. Review cash burn and funding needs: Analyze Profusa's cash position and operational expenses to understand its ongoing funding requirements and reliance on the equity facility.

Key Dates

• 2025-07-11: Business Combination — Profusa, Inc. completed its merger with NorthView Acquisition Corporation, marking its transition to a publicly traded entity.
• 2025-07-28: Purchase Agreement with Ascent Partners Fund LLC — Established a committed equity facility allowing Profusa to sell up to $100 million in common stock, providing potential future funding but also dilution risk.
• 2025-10-09: S-1 Filing — Registered up to 42,594,048 shares for resale, primarily related to the Ascent agreement and transaction costs, providing transparency on potential share overhang.

Glossary

S-1 Filing

The initial registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This document provides comprehensive details about Profusa's business, financial condition, risks, and the proposed resale of shares.)

Committed Equity Facility

An agreement where an investor commits to purchase a certain amount of a company's stock over a period, typically at the company's discretion. (Profusa's agreement with Ascent Partners Fund LLC provides a potential source of capital but involves pricing mechanisms that can lead to dilution.)

VWAP

Volume Weighted Average Price, a trading benchmark used to measure the average price of a security over a specified period, weighted by trading volume. (The purchase price for shares sold to Ascent is tied to the VWAP, influencing the effective price Profusa receives and potential dilution.)

Business Combination

A merger or acquisition transaction where two or more companies combine into a single entity. (Profusa's combination with NorthView Acquisition Corporation transformed it into a public company.)

Biointegrated Sensors

Medical devices designed to be implanted or integrated with the body to monitor physiological parameters. (This is the core technology Profusa is developing, aiming for long-term monitoring solutions like glucose and oxygen levels.)

Continuous Glucose Monitor (CGM)

A device that tracks glucose levels in the body continuously throughout the day and night. (Profusa's Lumee Glucose Platform is a CGM product under development, targeting a significant market need.)

Selling Stockholders

Existing shareholders who are registering their shares for resale to the public. (The S-1 filing primarily registers shares for resale by these stockholders, including those potentially selling shares acquired through the Ascent agreement.)

Beneficial Ownership Limitation

A clause in an agreement that restricts an investor from acquiring shares that would result in them owning more than a specified percentage of the company's outstanding stock. (This limits Ascent Partners Fund LLC's ownership to 9.99%, affecting the structure and timing of share sales.)

Year-Over-Year Comparison

This is the initial S-1 filing for Profusa, Inc. (formerly NorthView Acquisition Corporation) following its business combination. Therefore, a direct comparison of key financial metrics like revenue, net income, or margins against a prior period filing is not applicable at this stage. The filing primarily outlines the structure for potential future capital raises via a committed equity facility and registers shares for resale, rather than reporting historical operational performance.

Key Financial Figures

• $0.0001 — 4,048 shares of common stock, par value $0.0001 per share, of the Company (the " Common
• $0.33 — eported on the Nasdaq Global Market was $0.33 per share. We are a "smaller reporting
• $100,000,000 — ospectus. However, we may receive up to $100,000,000 in aggregate gross proceeds from Ascent
• $5,000,000 — Closing is limited to the lower of (a) $5,000,000 or (b) 100% of the average daily traded
• $0.01 — ment Warrants have an exercise price of $0.01 and may be exercised for cash or, if at
• $30,000 — ts Agreement in an amount not to exceed $30,000 upon our execution of the Purchase Agre
• $0 — an assumed purchase price per share of $0.34, representing the closing sale price
• $14.4 million — 25, we would only receive approximately $14.4 million in aggregate gross proceeds from the sa
• $100,000,000 m — ve aggregate proceeds equal to Ascent's $100,000,000 maximum aggregate purchase commitment ava

Filing Documents

• ea0258580-s1_profusa.htm (S-1) — 4075KB
• ea025858001ex5-1_profusa.htm (EX-5.1) — 12KB
• ea025858001ex23-1_profusa.htm (EX-23.1) — 2KB
• ea025858001ex23-2_profusa.htm (EX-23.2) — 2KB
• ea025858001ex-fee_profusa.htm (EX-FILING FEES) — 13KB
• image_001.jpg (GRAPHIC) — 16KB
• image_002.jpg (GRAPHIC) — 51KB
• image_003.jpg (GRAPHIC) — 60KB
• image_004.jpg (GRAPHIC) — 61KB
• image_005.jpg (GRAPHIC) — 94KB
• image_006.jpg (GRAPHIC) — 34KB
• image-007.jpg (GRAPHIC) — 50KB
• image_008.jpg (GRAPHIC) — 46KB
• image_009.jpg (GRAPHIC) — 132KB
• ex5-1_001.jpg (GRAPHIC) — 19KB
• ex5-1_002.jpg (GRAPHIC) — 6KB
• 0001213900-25-097860.txt ( ) — 19390KB
• ck0001859807-20250630.xsd (EX-101.SCH) — 135KB
• ck0001859807-20250630_cal.xml (EX-101.CAL) — 82KB
• ck0001859807-20250630_def.xml (EX-101.DEF) — 795KB
• ck0001859807-20250630_lab.xml (EX-101.LAB) — 1056KB
• ck0001859807-20250630_pre.xml (EX-101.PRE) — 804KB
• ea0258580-s1_profusa_htm.xml (XML) — 2577KB
• ea025858001ex-fee_profusa_htm.xml (XML) — 4KB

RISK FACTORS

RISK FACTORS 5 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 69 THE COMMITTED EQUITY FACILITY 70

USE OF PROCEEDS

USE OF PROCEEDS 75 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 76 DIVIDEND POLICY 90 MARKET INFORMATION 90

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 91

BUSINESS

BUSINESS 104 MANAGEMENT 131

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 136

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 138 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 139 SELLING STOCKHOLDERS 143 PLAN OF DISTRIBUTION 145

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 150 LEGAL MATTERS 154 EXPERTS 154 WHERE YOU CAN FIND MORE INFORMATION 154 INDEX TO FINANCIAL INFORMATION F-1 You should rely only on the information contained in this prospectus or any amendment or supplement to this prospectus. This prospectus is an offer to sell only the securities offered hereby, but only under the circumstances and in jurisdictions where it is lawful to do so. Neither we nor the Selling Stockholders have authorized anyone to provide you with information different from that contained in this prospectus or any amendment or supplement to this prospectus. Neither we nor the Selling Stockholders take any responsibility for, or can provide any assurance as to the reliability of, any information other than the information in this prospectus or any amendment or supplement to this prospectus. The information in this prospectus or any amendment or supplement to this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any amendment or supplement to this prospectus, as applicable, or any sale of the securities offered by this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. For Investors Outside the United States: The Selling Stockholders are offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Stockholders have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. i

View Full Filing

View this S-1 filing on SEC EDGAR